Personality dimensions of patients can change during the course of parkinson's disease.

Aged Character Female Humans Male Middle Aged Parkinson Disease / psychology Personality Disorders / psychology Personality Inventory

Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 20 10 2020
accepted: 22 12 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 11 5 2021
Statut: epublish

Résumé

Studies assessing personality dimensions by the "Temperament and Character Inventory" (TCI) have previously found an association between Parkinson's disease (PD) and lower Novelty Seeking and higher Harm Avoidance scores. Here, we aimed to describe personality dimensions of PD patients with motor fluctuations and compare them to a normative population and other PD populations. All PD patients awaiting Deep Brain Stimulation (DBS) answered the TCI before neurosurgery. Their results were compared to those of historical cohorts (a French normative population, a de novo PD population, and a PD population with motor fluctuations). Most personality dimensions of our 333 included PD patients with motor fluctuations who are candidates for DBS were different from those of the normative population and some were also different from those of the De Novo PD population, whereas they were similar to those of another population of PD patients with motor fluctuations. During the course of PD, personality dimensions can change in parallel with the development of motor fluctuations, either due to the evolution of the disease and/or dopaminergic treatments.

Sections du résumé

BACKGROUND
Studies assessing personality dimensions by the "Temperament and Character Inventory" (TCI) have previously found an association between Parkinson's disease (PD) and lower Novelty Seeking and higher Harm Avoidance scores. Here, we aimed to describe personality dimensions of PD patients with motor fluctuations and compare them to a normative population and other PD populations.
METHODS
All PD patients awaiting Deep Brain Stimulation (DBS) answered the TCI before neurosurgery. Their results were compared to those of historical cohorts (a French normative population, a de novo PD population, and a PD population with motor fluctuations).
RESULTS
Most personality dimensions of our 333 included PD patients with motor fluctuations who are candidates for DBS were different from those of the normative population and some were also different from those of the De Novo PD population, whereas they were similar to those of another population of PD patients with motor fluctuations.
CONCLUSIONS
During the course of PD, personality dimensions can change in parallel with the development of motor fluctuations, either due to the evolution of the disease and/or dopaminergic treatments.

Identifiants

DOI: 10.1371/journal.pone.0245142 PMID: 33411732 PMC: PMC7790271
pubmed: 33411732
doi: 10.1371/journal.pone.0245142
pii: PONE-D-20-32941
pmc: PMC7790271
doi:

Banques de données

ClinicalTrials.gov
['NCT02360683']

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0245142

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Neurol. 2010 Nov;257(Suppl 2):S276-83
pubmed: 21080189
Mov Disord. 2016 Aug;31(8):1103-13
pubmed: 27041545
Neurobiol Stress. 2015 Jan 1;1:164-173
pubmed: 25580450
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
Mov Disord. 2009 Aug 15;24(11):1561-70
pubmed: 19526584
J Parkinsons Dis. 2020;10(3):1057-1066
pubmed: 32444557
Parkinsonism Relat Disord. 2018 Apr;49:67-74
pubmed: 29358028
Psychiatry Res. 2000 Apr 24;94(1):67-76
pubmed: 10788679
Brain. 2009 Sep;132(Pt 9):2385-95
pubmed: 19416950
Eur J Neurosci. 2017 Jan;45(1):67-72
pubmed: 27623191
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13272-7
pubmed: 11687621
Psychiatr Genet. 1998 Summer;8(2):41-4
pubmed: 9686420
Biol Psychol. 1999 Oct;51(1):77-81
pubmed: 10579422
PeerJ. 2019 Oct 24;7:e7958
pubmed: 31660279
Biol Psychiatry. 1997 Aug 15;42(4):275-81
pubmed: 9270904
Psychiatr Genet. 2005 Jun;15(2):145-7
pubmed: 15900230
Nat Genet. 1996 Jan;12(1):81-4
pubmed: 8528258
Nat Genet. 1996 Jan;12(1):78-80
pubmed: 8528256
Arch Gen Psychiatry. 1993 Dec;50(12):975-90
pubmed: 8250684
Arch Neurol. 2006 Jul;63(7):969-73
pubmed: 16831966
J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1060-1064
pubmed: 29018160
Neurology. 2009 May 26;72(21 Suppl 4):S1-136
pubmed: 19470958
Psychiatry Res. 1996 Nov 1;65(1):61-4
pubmed: 8953662
J Neurol. 2016 Sep;263(9):1828-39
pubmed: 27334907
Am J Med Genet. 1998 May 8;81(3):257-67
pubmed: 9603615

Auteurs

Mathilde Boussac (M)

Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
ORCID: 0000-0002-3532-6743

Christophe Arbus (C)

Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.

Julia Dupouy (J)

Department of Neurology, Hospital of Avignon, Avignon, France.

Estelle Harroch (E)

Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.

Vanessa Rousseau (V)

Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.

Aurélie Croiset (A)

CERPPS-Study and Research Center in Psychopathology and Health Psychology, University of Toulouse II Jean-Jaurès, Toulouse, France.

Fabienne Ory-Magne (F)

Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.

Olivier Rascol (O)

Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.

Caroline Moreau (C)

Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.

Anne-Sophie Rolland (AS)

Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.

David Maltête (D)

Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM U1239, NS-PARK/FCRIN Network, Mont-Saint-Aignan, France.

Tiphaine Rouaud (T)

Clinique Neurologique, Hôpital Guillaume et René Laennec, NS-PARK/FCRIN Network, Boulevard Jacques Monod, Nantes, France.

Mylène Meyer (M)

Neurology Department, Nancy University Hospital, Nancy, France.

Sophie Drapier (S)

Behavior and Basal Ganglia Research Unit (EA 4712), University of Rennes 1, Rennes, France.
Department of Neurology, Rennes University Hospital, NS-PARK/FCRIN Network, Rennes, France.

Bruno Giordana (B)

Service Universitaire de Psychiatrie, Hôpital Pasteur 1, CHU de Nice, Nice, France.

Mathieu Anheim (M)

Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.
Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, NS-PARK/FCRIN Network, Strasbourg, France.

Elodie Hainque (E)

Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, NS-PARK/FCRIN Network, Paris, France.

Béchir Jarraya (B)

Pôle Neurosciences, Foch Hospital, Suresnes, France.
Université de Versailles Paris-Saclay, INSERM U992, CEA Neurospin, France.

Isabelle Benatru (I)

Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, NS-PARK/FCRIN Network, Poitiers, France.

Nicolas Auzou (N)

CHU de Bordeaux, Centre Expert Parkinson, Institut des maladies neuro-dégénératives, Bordeaux, France.

Lhaouas Belamri (L)

Hôpital Fondation A de Rothschild, Service de recherche clinique, Paris, France.

Mélissa Tir (M)

Department of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens, France.

Ana-Raquel Marques (AR)

Neurology Department, Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, NS-PARK/FCRIN Network, Clermont-Ferrand, France.

Stephane Thobois (S)

Univ Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Sud Charles Mérieux, Lyon, France.
CNRS, Institut des Sciences Cognitives, UMR 5229, Bron, France.
Centre Expert Parkinson, Hôpital Neurologique "Pierre Wertheimer", Hospices Civils de Lyon, NS-PARK/FCRIN Network, Lyon, France.

Alexandre Eusebio (A)

Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS 7289, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.

Jean Christophe Corvol (JC)

Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, NS-PARK/FCRIN Network, Paris, France.

David Devos (D)

Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.

Christine Brefel-Courbon (C)

Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Personality dimensions of patients can change...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Personnalité › Caractère › Personality dimensions of patients can change...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Personality dimensions of patients can change...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Personality dimensions of patients can change...
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Maladie de Parkinson › Personality dimensions of patients can change...
questionsmedicales.fr › Troubles mentaux › Troubles de la personnalité › Personality dimensions of patients can change...
questionsmedicales.fr › Disciplines et activités comportementales › Tests psychologiques › Tests de personnalité › Inventaire de personnalité › Personality dimensions of patients can change...